Building a Global Price Strategy: How Thelansis Helped a Biopharma Set the Right Launch Price Across 15 Markets
Background:
A biopharma
company was preparing to launch a first-in-class therapy in immunology TA. The
asset showed strong clinical promise, but its commercial team faced a familiar
challenge: every market had different payer expectations, and a single misstep
on price in one country could trigger ripple effects across the global
reference pricing network.
With 15
priority markets tied together through external reference pricing (ERP) rules,
the team needed a clear price corridor that protected the global floor price,
maintained headroom for future indications, and aligned with local payer
willingness to pay.
That’s where
Thelansis stepped in.
Problem
Statement:
The global
pricing team lacked:
- A harmonized view of payer elasticity
across the 15 markets
- A cross-market price corridor that
minimized reference price erosion
- A forward-looking assessment of ERP
spillover, especially from lower-priced markets
- Early guidance on how different price
stacks could influence HTA outcomes and budget impact reviews
They needed a
model that combined epidemiology, clinical value drivers, and payer logic
without losing real-world practicality.
Objective:
To build an
integrated pricing strategy that would help the company:
- Identify the “safe zone” price
corridor for each market
- Understand the knock-on impact of
list price decisions on ERP-linked countries
- Simulate payer reactions at different
price points
- Recommend a launch sequence that
protects price integrity globally
Approach:
1. Payer
Elasticity Mapping
Thelansis ran
a structured review of payer behaviour across the 15 markets, using:
- Past HTA decisions for therapies in
similar severity and budget classes
- Reimbursement thresholds tied to
therapeutic value, QALY signals, and unmet need
- Local budget environments and past
discount patterns
This gave us a
clear elasticity profile, aided in identifying which markets were value-driven,
which were cost-guarded, and where payers had historically accepted premium
pricing.
2. Price
Corridor Modelling
Instead of
using a theoretical model, Thelansis built a pragmatic corridor aligned with:
- Local willingness to pay ceilings
- Competitive benchmarks
- Expected confidential discount
expectations
- Risk of triggering renegotiations or
re-assessments
The corridor
showed upper and lower boundaries for each country, forming a consolidated
global picture of acceptable launch prices.
3. Reference
Pricing Impact Analysis
ERP
relationships were mapped using actual referencing rules (direct, indirect,
basket-based, average-based).
We created:
- Multiple launch sequence simulations
- Downward-pressure scenarios if a low
price leaked early
- Sensitivity runs for exchange rate
swings, clawbacks, and mandatory rebates
These
scenarios revealed how a suboptimal price in just 2 of the 15 markets could
reduce global revenue potential by nearly 18% within three years.
4.
Cross-Functional Insights
The analysis
was shared with the client’s market access, HEOR, forecasting, and regulatory
teams.
Together, we
aligned pricing recommendations with:
- Early economic value messages
- Budget impact narratives
- Phase III evidence readouts
- Anticipated payer objections
This ensured
pricing decisions were grounded in clinical value, not only financial
equations.
Outcome:
With
Thelansis’ pricing assessment, the biopharma was able to:
- Identify an optimal global list price
that balances payer tolerance with future indication expansion
- Sequence launches in a way that
protects ERPsensitive markets and avoids reference-driven price drops
- Strengthen HTA submissions with
realistic price-value justification
- Secure initial reimbursement
approvals in the first wave of markets without forced price cuts
Most
importantly, the team gained a clear, evidence-backed roadmap that prevented
unintended price erosion, preserving long-term value across all 15 markets.
Comments
Post a Comment